266 related articles for article (PubMed ID: 37999735)
1. Genomic alterations and diagnosis of renal cancer.
Zhang X; Bolck HA; Rupp NJ; Moch H
Virchows Arch; 2024 Feb; 484(2):323-337. PubMed ID: 37999735
[TBL] [Abstract][Full Text] [Related]
2. Clinico-pathological implications of the 2022 WHO Renal Cell Carcinoma classification.
Rizzo M; Caliò A; Brunelli M; Pezzicoli G; Ganini C; Martignoni G; Camillo P
Cancer Treat Rev; 2023 May; 116():102558. PubMed ID: 37060647
[TBL] [Abstract][Full Text] [Related]
3. New insights in the new WHO classification of adult renal tumors.
Hes O; Michalová K; Pivovarčíková K
Cesk Patol; 2022; 67(4):187-191. PubMed ID: 36513503
[TBL] [Abstract][Full Text] [Related]
4. The New WHO Category of "Molecularly Defined Renal Carcinomas": Clinical and Diagnostic Features and Management Implications.
Kanakaraj J; Chang J; Hampton LJ; Smith SC
Urol Oncol; 2024 Jul; 42(7):211-219. PubMed ID: 38519377
[TBL] [Abstract][Full Text] [Related]
5. Report From the International Society of Urological Pathology (ISUP) Consultation Conference on Molecular Pathology of Urogenital Cancers: III: Molecular Pathology of Kidney Cancer.
Williamson SR; Gill AJ; Argani P; Chen YB; Egevad L; Kristiansen G; Grignon DJ; Hes O
Am J Surg Pathol; 2020 Jul; 44(7):e47-e65. PubMed ID: 32251007
[TBL] [Abstract][Full Text] [Related]
6. Diagnosis of uncommon renal epithelial neoplasms: performances of fluorescence in situ hybridization.
Beaumont M; Dugay F; Kammerer-Jacquet SF; Jaillard S; Cabillic F; Mathieu R; Verhoest G; Bensalah K; Rioux-Leclercq N; Belaud-Rotureau MA;
Hum Pathol; 2019 Oct; 92():81-90. PubMed ID: 31437522
[TBL] [Abstract][Full Text] [Related]
7. Translocation carcinomas of the kidney.
Argani P
Genes Chromosomes Cancer; 2022 May; 61(5):219-227. PubMed ID: 34704642
[TBL] [Abstract][Full Text] [Related]
8. Update on Selected High-grade Renal Cell Carcinomas of the Kidney: FH-deficient, ALK-rearranged, and Medullary Carcinomas.
Chen YB
Adv Anat Pathol; 2024 Mar; 31(2):118-125. PubMed ID: 38145398
[TBL] [Abstract][Full Text] [Related]
9. Minimally invasive cytologic evaluation leading to the diagnosis of TFE3-rearranged renal cell carcinoma: A case report.
Gama A; Sukhanova M; Choy B
Diagn Cytopathol; 2022 Dec; 50(12):E382-E385. PubMed ID: 35975764
[TBL] [Abstract][Full Text] [Related]
10. What's new in the WHO 2022 classification of kidney tumours?
Alaghehbandan R; Siadat F; Trpkov K
Pathologica; 2022 Feb; 115(1):8-22. PubMed ID: 36645398
[TBL] [Abstract][Full Text] [Related]
11. Emerging Entities in Renal Neoplasia.
Mehra R; Smith SC; Divatia M; Amin MB
Surg Pathol Clin; 2015 Dec; 8(4):623-56. PubMed ID: 26612218
[TBL] [Abstract][Full Text] [Related]
12. The 2022 World Health Organization Classification of Tumours of the Urinary System and Male Genital Organs-Part A: Renal, Penile, and Testicular Tumours.
Moch H; Amin MB; Berney DM; Compérat EM; Gill AJ; Hartmann A; Menon S; Raspollini MR; Rubin MA; Srigley JR; Hoon Tan P; Tickoo SK; Tsuzuki T; Turajlic S; Cree I; Netto GJ
Eur Urol; 2022 Nov; 82(5):458-468. PubMed ID: 35853783
[TBL] [Abstract][Full Text] [Related]
13. Assessing Genomic Copy Number Alterations as Best Practice for Renal Cell Neoplasia: An Evidence-Based Review from the Cancer Genomics Consortium Workgroup.
Liu YJ; Houldsworth J; Emmadi R; Dyer L; Wolff DJ
Cancer Genet; 2020 Jun; 244():40-54. PubMed ID: 32434132
[TBL] [Abstract][Full Text] [Related]
14. TRIM63 is a sensitive and specific biomarker for MiT family aberration-associated renal cell carcinoma.
Wang XM; Zhang Y; Mannan R; Skala SL; Rangaswamy R; Chinnaiyan A; Su F; Cao X; Zelenka-Wang S; McMurry L; Xiao H; Spratt DE; Sangoi AR; Shao L; Betz BL; Brown N; Tickoo SK; McKenney JK; Argani P; Gupta S; Reuter VE; Chinnaiyan AM; Dhanasekaran SM; Mehra R
Mod Pathol; 2021 Aug; 34(8):1596-1607. PubMed ID: 33854184
[TBL] [Abstract][Full Text] [Related]
15.
Wangsiricharoen S; Zhong M; Ranganathan S; Matoso A; Argani P
Int J Surg Pathol; 2021 Oct; 29(7):808-814. PubMed ID: 33729862
[TBL] [Abstract][Full Text] [Related]
16. Exploration of clinicopathological features of rearranged renal cell carcinoma and TFE3, TFEB, and ALK staining performance in renal entities.
Liu Y; Li X; Fan Y; Xu H; Gu Y; Dong L; Zhou L; Yang X; Wang C
Heliyon; 2023 Apr; 9(4):e15159. PubMed ID: 37089387
[TBL] [Abstract][Full Text] [Related]
17. The classification of pediatric and young adult renal cell carcinomas registered on the children's oncology group (COG) protocol AREN03B2 after focused genetic testing.
Cajaiba MM; Dyer LM; Geller JI; Jennings LJ; George D; Kirschmann D; Rohan SM; Cost NG; Khanna G; Mullen EA; Dome JS; Fernandez CV; Perlman EJ
Cancer; 2018 Aug; 124(16):3381-3389. PubMed ID: 29905933
[TBL] [Abstract][Full Text] [Related]
18. A review of ALK-rearranged renal cell carcinomas with a focus on clinical and pathobiological aspects.
Kuroda N; Sugawara E; Kusano H; Yuba Y; Yorita K; Takeuchi K
Pol J Pathol; 2018; 69(2):109-113. PubMed ID: 30351856
[TBL] [Abstract][Full Text] [Related]
19. Lessons from 801 clinical TFE3/TFEB fluorescence in situ hybridization assays performed on renal cell carcinoma suspicious for MiTF family aberrations.
Wang XM; Shao L; Xiao H; Myers JL; Pantanowitz L; Skala SL; Udager AM; Vaishampayan U; Mannan R; Dhanasekaran SM; Chinnaiyan AM; Betz BL; Brown N; Mehra R
Am J Clin Pathol; 2023 Dec; 160(6):549-554. PubMed ID: 37499055
[TBL] [Abstract][Full Text] [Related]
20. Morphologic, Molecular, and Taxonomic Evolution of Renal Cell Carcinoma: A Conceptual Perspective With Emphasis on Updates to the 2016 World Health Organization Classification.
Udager AM; Mehra R
Arch Pathol Lab Med; 2016 Oct; 140(10):1026-37. PubMed ID: 27684973
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
